Production (Stage)
Sharp Therapeutics Corp.
SHRX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 349.95% | -201.28% | -201.28% | 316.78% | -30.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.19% | -30.14% | -30.14% | 102.82% | 6.08% |
| Operating Income | -117.19% | 30.14% | 30.14% | -102.82% | -6.08% |
| Income Before Tax | -164.60% | 88.01% | 88.01% | -110.53% | -45.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -164.60% | 88.01% | 88.01% | -110.53% | -45.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.60% | 88.01% | 88.01% | -110.53% | -45.98% |
| EBIT | -117.19% | 30.14% | 30.14% | -102.82% | -6.08% |
| EBITDA | -118.94% | 29.88% | 28.86% | -113.79% | -10.76% |
| EPS Basic | 98.69% | 94.27% | 94.27% | -110.50% | -45.76% |
| Normalized Basic EPS | 98.22% | 79.74% | 79.74% | -92.12% | -18.39% |
| EPS Diluted | 98.69% | 94.27% | 94.27% | -110.50% | -45.76% |
| Normalized Diluted EPS | 98.22% | 79.74% | 79.74% | -92.12% | -18.39% |
| Average Basic Shares Outstanding | 20,159.01% | 108.86% | 108.86% | 0.07% | 0.14% |
| Average Diluted Shares Outstanding | 20,159.01% | 108.86% | 108.86% | 0.07% | 0.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |